FDA approves Takeda's EOHILIA as first oral treatment for eosinophilic esophagitis in US aged 11+, based on clinical trial data.

FDA approves Takeda's EOHILIA (budesonide oral suspension), the first oral treatment in the U.S. for eosinophilic esophagitis (EoE) in individuals 11 years and older. The drug will be available by the end of February in 2mg/10mL single-dose stick packs. The FDA's approval is based on data from two 12-week clinical trials demonstrating efficacy and safety. Takeda is currently assessing the financial impact of this approval on its fiscal year ending March 31, 2024.

February 12, 2024
4 Articles